Hangzhou Tigermed Consulting (300347) - Net Assets
Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has net assets worth CN¥24.26 Billion CNY (≈ $3.55 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥28.36 Billion ≈ $4.15 Billion USD) and total liabilities (CN¥4.10 Billion ≈ $600.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300347 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥24.26 Billion |
| % of Total Assets | 85.53% |
| Annual Growth Rate | 48.31% |
| 5-Year Change | 17.72% |
| 10-Year Change | 1218.44% |
| Growth Volatility | 97.34 |
Hangzhou Tigermed Consulting - Net Assets Trend (2009–2025)
This chart illustrates how Hangzhou Tigermed Consulting's net assets have evolved over time, based on quarterly financial data. Also explore Hangzhou Tigermed Consulting (300347) total assets for the complete picture of this company's asset base.
Annual Net Assets for Hangzhou Tigermed Consulting (2009–2025)
The table below shows the annual net assets of Hangzhou Tigermed Consulting from 2009 to 2025. For live valuation and market cap data, see how much is Hangzhou Tigermed Consulting worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥24.26 Billion ≈ $3.55 Billion |
+0.80% |
| 2024-12-31 | CN¥24.06 Billion ≈ $3.52 Billion |
-1.59% |
| 2023-12-31 | CN¥24.45 Billion ≈ $3.58 Billion |
+7.82% |
| 2022-12-31 | CN¥22.68 Billion ≈ $3.32 Billion |
+10.07% |
| 2021-12-31 | CN¥20.61 Billion ≈ $3.02 Billion |
+15.38% |
| 2020-12-31 | CN¥17.86 Billion ≈ $2.61 Billion |
+223.45% |
| 2019-12-31 | CN¥5.52 Billion ≈ $807.94 Million |
+68.74% |
| 2018-12-31 | CN¥3.27 Billion ≈ $478.82 Million |
+16.81% |
| 2017-12-31 | CN¥2.80 Billion ≈ $409.92 Million |
+52.26% |
| 2016-12-31 | CN¥1.84 Billion ≈ $269.22 Million |
+72.60% |
| 2015-12-31 | CN¥1.07 Billion ≈ $155.98 Million |
+16.25% |
| 2014-12-31 | CN¥916.90 Million ≈ $134.17 Million |
+21.42% |
| 2013-12-31 | CN¥755.14 Million ≈ $110.50 Million |
+8.76% |
| 2012-12-31 | CN¥694.32 Million ≈ $101.60 Million |
+375.48% |
| 2011-12-31 | CN¥146.03 Million ≈ $21.37 Million |
+52.45% |
| 2010-12-31 | CN¥95.79 Million ≈ $14.02 Million |
+116.43% |
| 2009-12-31 | CN¥44.26 Million ≈ $6.48 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou Tigermed Consulting's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 392486.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥9.32 Billion | 44.47% |
| Other Components | CN¥11.64 Billion | 55.53% |
| Total Equity | CN¥20.96 Billion | 100.00% |
Hangzhou Tigermed Consulting Competitors by Market Cap
The table below lists competitors of Hangzhou Tigermed Consulting ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sulzer AG
SW:SUN
|
$5.96 Billion |
|
Grupo Financiero Galicia S.A.
BA:GGAL
|
$5.96 Billion |
|
Chord Energy Corp
NASDAQ:CHRD
|
$5.96 Billion |
|
Shanghai Commercial & Savings Bank Ltd
TW:5876
|
$5.97 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
$5.96 Billion |
|
Chemed Corp
NYSE:CHE
|
$5.96 Billion |
|
Bank Millennium S.A.
WAR:MIL
|
$5.95 Billion |
|
Definity Financial Corp
TO:DFY
|
$5.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou Tigermed Consulting's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,670,653,449 to 20,959,506,515, a change of 288,853,066 (1.4%).
- Net income of 887,890,076 contributed positively to equity growth.
- Dividend payments of 343,659,038 reduced retained earnings.
- Other factors decreased equity by 255,377,972.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥887.89 Million | +4.24% |
| Dividends Paid | CN¥343.66 Million | -1.64% |
| Other Changes | CN¥-255.38 Million | -1.22% |
| Total Change | CN¥- | 1.40% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou Tigermed Consulting's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 530.24x to 2.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.10 | CN¥55.20 | x |
| 2010-12-31 | CN¥0.20 | CN¥55.20 | x |
| 2011-12-31 | CN¥0.29 | CN¥55.20 | x |
| 2012-12-31 | CN¥1.29 | CN¥55.20 | x |
| 2013-12-31 | CN¥1.16 | CN¥55.20 | x |
| 2014-12-31 | CN¥1.33 | CN¥55.20 | x |
| 2015-12-31 | CN¥1.54 | CN¥55.20 | x |
| 2016-12-31 | CN¥2.31 | CN¥55.20 | x |
| 2017-12-31 | CN¥3.37 | CN¥55.20 | x |
| 2018-12-31 | CN¥3.79 | CN¥55.20 | x |
| 2019-12-31 | CN¥5.67 | CN¥55.20 | x |
| 2020-12-31 | CN¥20.17 | CN¥55.20 | x |
| 2021-12-31 | CN¥20.81 | CN¥55.20 | x |
| 2022-12-31 | CN¥22.63 | CN¥55.20 | x |
| 2023-12-31 | CN¥24.31 | CN¥55.20 | x |
| 2024-12-31 | CN¥23.95 | CN¥55.20 | x |
| 2025-12-31 | CN¥24.34 | CN¥55.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou Tigermed Consulting utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.99%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.35x
- Recent ROE (4.24%) is below the historical average (14.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 18.41% | 12.42% | 0.93x | 1.59x | CN¥3.56 Million |
| 2010 | 33.96% | 25.81% | 1.02x | 1.28x | CN¥22.37 Million |
| 2011 | 33.86% | 24.73% | 1.03x | 1.32x | CN¥33.68 Million |
| 2012 | 9.82% | 26.64% | 0.35x | 1.06x | CN¥-1.26 Million |
| 2013 | 12.64% | 27.95% | 0.42x | 1.09x | CN¥19.66 Million |
| 2014 | 14.53% | 20.09% | 0.46x | 1.57x | CN¥39.14 Million |
| 2015 | 15.59% | 16.33% | 0.59x | 1.61x | CN¥56.04 Million |
| 2016 | 8.65% | 11.98% | 0.49x | 1.47x | CN¥-22.03 Million |
| 2017 | 12.08% | 17.84% | 0.47x | 1.44x | CN¥51.91 Million |
| 2018 | 16.63% | 20.52% | 0.49x | 1.65x | CN¥188.21 Million |
| 2019 | 19.92% | 30.02% | 0.37x | 1.79x | CN¥419.13 Million |
| 2020 | 10.86% | 54.81% | 0.16x | 1.21x | CN¥137.92 Million |
| 2021 | 15.86% | 55.13% | 0.22x | 1.31x | CN¥1.06 Billion |
| 2022 | 10.25% | 28.32% | 0.26x | 1.40x | CN¥48.25 Million |
| 2023 | 9.63% | 27.42% | 0.25x | 1.41x | CN¥-77.83 Million |
| 2024 | 1.96% | 6.14% | 0.23x | 1.39x | CN¥-1.66 Billion |
| 2025 | 4.24% | 12.99% | 0.24x | 1.35x | CN¥-1.21 Billion |
Industry Comparison
This section compares Hangzhou Tigermed Consulting's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,633,426,415
- Average return on equity (ROE) among peers: 21.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou Tigermed Consulting (300347) | CN¥24.26 Billion | 18.41% | 0.17x | $5.96 Billion |
| Berry Genomics Co Ltd (000710) | $2.33 Billion | -10.83% | 0.37x | $516.80 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.77 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $3.27 Billion | 11.90% | 0.41x | $1.09 Billion |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.52 Billion | 7.88% | 0.42x | $567.44 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $928.17 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $501.67 Million | 15.17% | 0.15x | $573.30 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.44 Billion |
| Amoy Diagnostics Co Ltd (300685) | $756.74 Million | 16.75% | 0.08x | $1.16 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $130.79 Million | 64.49% | 1.52x | $605.42 Million |
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more